There is no generic version of Ozempic available in the United States. The active ingredient, semaglutide, is protected by patents that aren’t set to expire until 2032 in the U.S., meaning a true FDA-approved generic is likely years away. However, the landscape is more complicated than a simple “no,” because compounded versions, counterfeit products, and a newly approved generic of an older, related drug all factor into what you might encounter.
Why a Generic Doesn’t Exist Yet
Novo Nordisk, the company that makes Ozempic, holds U.S. patent protection through 2032. Until that patent expires or is successfully challenged, no other manufacturer can sell an FDA-approved generic semaglutide injection in the United States. Novo Nordisk has also settled patent lawsuits with companies that attempted to challenge its key patent, and while the settlement terms are confidential, they likely include agreed-upon dates for generic entry, possibly with royalty payments.
The picture looks different outside the U.S. Novo Nordisk’s patent in China expires in 2026, and several major Chinese pharmaceutical companies are planning to launch their own semaglutide products between 2025 and 2027. Those products won’t be available in the U.S., but they signal that generic competition is building globally.
What About Compounded Semaglutide?
You may have seen clinics, telehealth companies, or compounding pharmacies advertising semaglutide injections at a fraction of Ozempic’s price. These are compounded versions, not generics. The distinction matters.
Compounding pharmacies were previously allowed to produce semaglutide because it appeared on the FDA’s drug shortage list. When a brand-name drug is in shortage, compounders can legally make their own version to fill the gap. As of now, semaglutide no longer appears on the FDA’s shortage list, which significantly restricts the legal basis for compounding it. Individual compounding pharmacies operating under Section 503A of federal law can still prepare compounded drugs for specific patients with a prescription, but they cannot routinely produce what are essentially copies of commercially available products.
The FDA has raised pointed safety concerns about compounded semaglutide. Some compounders have been using salt forms of the molecule, such as semaglutide sodium or semaglutide acetate, which are chemically different from the semaglutide in Ozempic. The FDA has stated it does not have information on whether these salt forms share the same properties as the approved drug and is not aware of any lawful basis for using them in compounding. In practical terms, this means a compounded semaglutide injection may not work the same way in your body, and its safety profile is unknown.
Counterfeit Ozempic Is a Real Risk
The FDA has identified multiple batches of counterfeit Ozempic pens that entered the U.S. drug supply chain. These are not off-brand or generic products. They are fakes designed to look like real Ozempic, and using them is dangerous.
Three specific lot numbers have been flagged: PAR1229, PAR0362, and NAR0074. With lot PAR1229, the counterfeit can be spotted by checking the label. On the fake, the “EXP/LOT” text sits to the left of the expiration date and lot number. On a real Ozempic pen, that text appears above the date and lot number. If you received Ozempic from any source other than a verified pharmacy and something about the packaging looks off, check the lot number against the FDA’s alerts before using it.
A Generic GLP-1 Drug Does Exist
While there’s no generic Ozempic specifically, the FDA has approved a generic version of liraglutide, which is the active ingredient in Victoza (for type 2 diabetes) and Saxenda (for weight management). Liraglutide belongs to the same drug class as semaglutide. Both are GLP-1 receptor agonists, meaning they mimic a gut hormone that helps regulate blood sugar and appetite. The key difference is that liraglutide requires daily injections, while semaglutide is a once-weekly shot, and semaglutide has generally shown greater effects on weight loss and blood sugar reduction in clinical trials.
Still, a generic liraglutide injection could be a meaningful option if cost is the primary barrier. It’s worth discussing with your prescriber whether the older drug meets your needs, especially given the price gap.
What Ozempic Costs Right Now
Without insurance, Ozempic is expensive. Novo Nordisk’s own pricing programs give a sense of the range: new patients can pay $199 per month for the first two months on the lower doses, while existing patients pay $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses, and $499 per month for the 2 mg dose. (A “month” in these programs means 28 days.) If you have commercial insurance, a manufacturer savings card can bring the cost down to as little as $25 for up to a three-month supply.
For people who are uninsured or on Medicare, Novo Nordisk runs a Patient Assistance Program that provides Ozempic at no cost to qualifying patients. Eligibility requires U.S. citizenship or legal residency, a total household income at or below 200% of the federal poverty level, and either Medicare or no insurance at all. You can’t qualify if you’re eligible for Medicaid, the Medicare Low Income Subsidy, or VA benefits, though you can apply with a Medicaid denial letter if your income otherwise qualifies.
How Semaglutide Works
Semaglutide mimics GLP-1, a hormone your gut naturally releases after eating. This hormone signals your pancreas to produce insulin, slows digestion so you feel full longer, and acts on appetite centers in the brain to reduce hunger. Your body normally breaks down GLP-1 within minutes, but semaglutide is engineered to resist that breakdown, which is why a single weekly injection can maintain its effects for seven days.
This mechanism is why Ozempic is FDA-approved for type 2 diabetes (and its sibling Wegovy, the same molecule at a higher dose, is approved for weight management). Any future generic would need to demonstrate it activates these same pathways with equivalent effectiveness.
What to Expect in Coming Years
The 2032 U.S. patent expiration sets the outer boundary, but the confidential settlements Novo Nordisk reached with generic manufacturers could allow entry before that date. The generic drug approval process for complex injectable biologics like semaglutide is also more involved than for a simple pill, so even after patents expire, it may take additional time for generics to reach pharmacy shelves. For now, the realistic options are the brand-name product, manufacturer savings programs, or discussing alternative GLP-1 medications with your doctor.